Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Joo Hye Song, Sung Noh Hong, Jung Eun Lee, Kyunga Kim, Tae Jun Kim, Eun Ran Kim, Dong Kyung Chang & Young-Ho Kim. (2019) C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease. Scandinavian Journal of Gastroenterology 54:7, pages 876-885.
Read now
Read now
G. Girolomoni, C. E. M. Griffiths, J. Krueger, F. O. Nestle, J-F. Nicolas, J. C. Prinz, L. Puig, M. Ståhle, P. C. M. van de Kerkhof, M. Allez, P. Emery & C. Paul. (2015) Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. Journal of Dermatological Treatment 26:2, pages 103-112.
Read now
Read now
Articles from other publishers (30)
Mahmoud H. Mosli, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Amr M. Khardaly, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi & Badr Al-Bawardy. (2023) Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease. Saudi Journal of Gastroenterology 29:Suppl 1, pages S1-S35.
Crossref
Crossref
Derrick D. Eichele & Renee Young. (2019) Medical Management of Inflammatory Bowel Disease. Surgical Clinics of North America 99:6, pages 1223-1235.
Crossref
Crossref
Roy Frei, Nicolas Fournier, Jonas Zeitz, Michael Scharl, Bernhard Morell, Thomas Greuter, Philipp Schreiner, Benjamin Misselwitz, Ekaterina Safroneeva, Alain M Schoepfer, Stephan R Vavricka, Gerhard Rogler & Luc Biedermann. (2019) Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn’s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. Journal of Crohn's and Colitis 13:10, pages 1292-1301.
Crossref
Crossref
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah & Rupert W L Leong. (2019) Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Journal of Gastroenterology and Hepatology 34:8, pages 1296-1315.
Crossref
Crossref
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah & Rupert WL Leong. (2019) Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia. Intestinal Research 17:3, pages 285-310.
Crossref
Crossref
Candace L. Beilman, Erin Kirwin, Christopher Ma, Christopher McCabe, Richard N. Fedorak & Brendan Halloran. (2019) Early Initiation of Tumor Necrosis Factor Antagonist–Based Therapy for Patients With Crohn’s Disease Reduces Costs Compared With Late Initiation. Clinical Gastroenterology and Hepatology 17:8, pages 1515-1524.e4.
Crossref
Crossref
Süleyman Günay, Ferda Taşova, Huriye Erbak Yılmaz, Zehra Betül Paköz & Cem Çekiç. (2019) Serum Resolvin E1 Levels and Its Relationship with Disease Activity in Ulcerative Colitis. Gastroenterology Research and Practice 2019, pages 1-5.
Crossref
Crossref
Navjot Deol, Tran M Nguyen, Claire E Parker, Reena Khanna, Brian G Feagan, John K MacDonald & Vipul Jairath. (2017) Infliximab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Robert R. Cima & John H. Pemberton. 2017. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
505
517
.
Miguel D Regueiro, Julia B Greer & Stephen B Hanauer. (2016) Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. The American Journal of Gastroenterology Supplements 3:3, pages 8-16.
Crossref
Crossref
Akshay Kapoor, Vidyut Bhatia & Anupam Sibal. (2016) Pediatric inflammatory bowel disease. Indian Pediatrics 53:11, pages 993-1002.
Crossref
Crossref
Wei-Chen Lin, Ming-Jen Chen, Cheng-Hsin Chu, Tsang-En Wang, Horng-Yuan Wang, Shou-Chuan Shih & Chen-Wang Chang. (2016) Crohn's Disease: Specific Concerns in the Elderly. International Journal of Gerontology 10:3, pages 126-130.
Crossref
Crossref
Ana Gutiérrez, Pedro Zapater, Oriol Juanola, Laura Sempere, Marifé García, Raquel Laveda, Antonio Martínez, Michael Scharl, José M González-Navajas, José Such, Reiner Wiest, Gerhard Rogler & Rubén Francés. (2016) Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn’s Disease. American Journal of Gastroenterology 111:4, pages 529-540.
Crossref
Crossref
Gerda C Leitner. (2016) Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World Journal of Gastrointestinal Pharmacology and Therapeutics 7:1, pages 5.
Crossref
Crossref
Allan Boal & Chris Probert. (2015) The role of budesonide in the management of Crohn's disease. Gastrointestinal Nursing 13:10, pages 26-33.
Crossref
Crossref
Yun Qiu, Ren Mao, Bai-li Chen, Yao He, Zhi-rong Zeng & Min-hu Chen. (2015) Systematic Review with Meta-analysis of Prospective Studies: Anti-tumour Necrosis Factor for Prevention of Postoperative Crohn’s Disease Recurrence. Journal of Crohn's and Colitis 9:10, pages 918-927.
Crossref
Crossref
Daniel O. Erim, Nirosha Mahendraratnam, Phillip N. Okafor & Stephanie B. Wheeler. (2015) The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn’s Disease Patients with Adalimumab Non-response in the USA. Journal of Crohn's and Colitis 9:8, pages 669-675.
Crossref
Crossref
Geert R. D'Haens, R. Balfour Sartor, Mark S. Silverberg, Joel Petersson & Paul Rutgeerts. (2014) Future directions in inflammatory bowel disease management. Journal of Crohn's and Colitis 8:8, pages 726-734.
Crossref
Crossref
Mark Bounthavong, Nermeen Madkour & Rashid Kazerooni. (2014) Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population. PeerJ 2, pages e385.
Crossref
Crossref
Ana Gutiérrez, Michael Scharl, Laura Sempere, Ernst Holler, Pedro Zapater, Isabel Almenta, José M González-Navajas, José Such, Reiner Wiest, Gerhard Rogler & Rubén Francés. (2014) Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut 63:2, pages 272-280.
Crossref
Crossref
Lukáš Rendl & Valérie Tóthová. (2013) Possibilities of improvement of life quality in patients with Crohn disease from nurse's view. Kontakt 15:2, pages 128-134.
Crossref
Crossref
Ioannis E KoutroubakisAnna BuchnerWojciech BlonskiGary R Lichtenstein. 2013. Advances in the Management of Inflammatory Bowel Disease. Advances in the Management of Inflammatory Bowel Disease
104
122
.
Zhenhua Xu, Hugh M. Davis & Honghui Zhou. (2013) Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacology & Therapeutics 137:2, pages 225-247.
Crossref
Crossref
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe & William J Sandborn. (2012) Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry. American Journal of Gastroenterology 107:9, pages 1409-1422.
Crossref
Crossref
Koji Yoshida, Ken Fukunaga, Hiroki Ikeuchi, Koji Kamikozuru, Nobuyuki Hida, Yoshio Ohda, Yoko Yokoyama, Masaki Iimuro, Naohisa Takeda, Kyoichi Kato, Risa Kikuyama, Kazuko Nagase, Kazutoshi Hori, Shiro Nakamura, Hiroto Miwa & Takayuki Matsumoto. (2012) Scheduled infliximab monotherapy to prevent recurrence of Crohnʼs disease following ileocolic or ileal resection: A 3-year prospective randomized open trial. Inflammatory Bowel Diseases 18:9, pages 1617-1623.
Crossref
Crossref
Michael S. Kasparek, Andreas Bruckmeier, Florian Beigel, Mario H. Müller, Stephan Brand, Ulrich Mansmann, Karl-Walter Jauch, Thomas Ochsenkühn & Martin E. Kreis. (2012) Infliximab Does Not Affect Postoperative Complication Rates in Crohnʼs Patients Undergoing Abdominal Surgery. Inflammatory Bowel Diseases 18:7, pages 1207-1213.
Crossref
Crossref
Laura A. Johnson, Amy Luke, Kay Sauder, David S. Moons, Jeffrey C. Horowitz & Peter D.R. Higgins. (2012) Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top-Down” approach to intestinal fibrosis in mice. Inflammatory Bowel Diseases 18:3, pages 460-471.
Crossref
Crossref
Robert R. Cima & John H. Pemberton. 2012. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
549
564
.
Wojciech Blonski, Anna M Buchner & Gary R Lichtenstein. (2011) Inflammatory bowel disease therapy: current state-of-the-art. Current Opinion in Gastroenterology, pages 1.
Crossref
Crossref
Thomas W. Lee & Richard N. Fedorak. (2010) Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology. Gastroenterology Clinics of North America 39:3, pages 543-557.
Crossref
Crossref